Shire, the UK-based pharmaceutical company specialising in treatments for attention deficit hyperactivity disorder (ADHD), has set up a new website that gives access to summaries of results from selected Shire-sponsored clinical trials.

The information is available at the new site,, as well as through a link on the Shire corporate website ( or through, the website managed by the US pharmaceutical industry association, PhRMA. The Shire site includes summaries of results from Phase II-IV trials with four of the company’s medicines: the ADHD treatment Adderall XR (mixed amphetamine salts), the ADHD transdermal patch Daytrana (methylphenidate), Lialda (mesalamine) for ulcerative colitis and ProAmantine (midodrine) for raising low blood pressure.

“The creation of this new website helps us achieve our goal to ensure that patients and their families, as well as physicians and other healthcare providers, have access to accurate information related to Shire medicines,” said Dr Eliseo Salinas, the company’s chief scientific officer. “It’s important for patients and their caregivers to understand all aspects associated with the treatment options they may be considering, and this new tool, which offers clinical trial data dating back to 2002, provides a central source to this information for Shire-sponsored trials of our medicines.”

While other companies as well as industry associations have moved to make results of clinical trials with their products more generally available, the trend has gained momentum with the recent passage of the Food and Drug Administration Amendments Act of 2007 in the US. Under the Act, – the existing on-line registry run by the National Institutes of Health – will expand to incorporate not only mandatory registration of all Phase II-IV trials with compounds subject to the Federal Food, Drug, and Cosmetic Act but also some elements of clinical trial results.